~9 spots leftby Mar 2026

Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease

Recruiting in Palo Alto (17 mi)
+15 other locations
Age: Any Age
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Pfizer

Trial Summary

What is the purpose of this trial?This trial tests a new drug called PF-07209326 to see if it is safe and how it behaves in the body. It starts with healthy people and then moves to those with sickle cell disease. The study checks how the drug moves through and affects the body.

Eligibility Criteria

Inclusion Criteria

1. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs).

Participant Groups

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment for SCDExperimental Treatment1 Intervention
Participants will receive a multiple dose of subcutaneous PF-07209326
Group II: Treatment Healthy ParticipantsExperimental Treatment1 Intervention
Participants will receive single ascending doses of subcutaneous (SC) or intravenous PF-07209326
Group III: Placebo Healthy ParticipantsPlacebo Group1 Intervention
Participants will receive matching placebo

Find A Clinic Near You

Research locations nearbySelect from list below to view details:
Howard University HospitalWashington, United States
CUIMC Research PharmacyNew York, NY
Columbia University Medical Center - Herbert Irving PavilionNew York, NY
CUMC Research PharmacyNew York, NY
More Trial Locations
Loading ...

Who is running the clinical trial?

PfizerLead Sponsor

References